Cargando…

Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow(®) CS

PURPOSE: To assess clinical characteristics and device satisfaction of patients with chronic obstructive pulmonary disease (COPD) treated with glycopyrrolate/eFlow(®) Closed System (CS) nebulizer (further referred to as eFlow) under real-world conditions. PARTICIPANTS AND METHODS: Patients with COPD...

Descripción completa

Detalles Bibliográficos
Autores principales: Stephenson, Judith J, Dembek, Carole, Caldwell-Tarr, Amanda, Conto, Rebecca M, Paullin, Mark, Kerwin, Edward M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369372/
https://www.ncbi.nlm.nih.gov/pubmed/32764916
http://dx.doi.org/10.2147/COPD.S248760
_version_ 1783560766617550848
author Stephenson, Judith J
Dembek, Carole
Caldwell-Tarr, Amanda
Conto, Rebecca M
Paullin, Mark
Kerwin, Edward M
author_facet Stephenson, Judith J
Dembek, Carole
Caldwell-Tarr, Amanda
Conto, Rebecca M
Paullin, Mark
Kerwin, Edward M
author_sort Stephenson, Judith J
collection PubMed
description PURPOSE: To assess clinical characteristics and device satisfaction of patients with chronic obstructive pulmonary disease (COPD) treated with glycopyrrolate/eFlow(®) Closed System (CS) nebulizer (further referred to as eFlow) under real-world conditions. PARTICIPANTS AND METHODS: Patients with COPD currently using eFlow were identified by the study sponsor. Consenting patients who met study inclusion criteria completed a cross-sectional survey that included a device satisfaction questionnaire. Means, medians, and standard deviations were calculated. RESULTS: Sixty-six patients met inclusion criteria and completed the survey. Participants’ mean ± standard deviation age was 64.9 ± 11.9 years and the majority were white (86.4%) and female (59.1%). Almost two-thirds were former smokers. Thirty-nine (59.1%) reported their COPD to be severe/very severe and 38 (57.6%) reported a COPD exacerbation resulting in a hospitalization, ER visit, or medication modification over the past 12 months. Among 55 participants who had previously used another type of nebulizer, 44 (80%) were overall “much more”/“somewhat more” satisfied with the eFlow compared with their previous nebulizer(s). Regardless of prior nebulizer use, 60 (90.9%) participants were “satisfied”/“very satisfied” overall with the eFlow. Assembly and disassembly, operation, and cleaning were perceived as being “easy”/“very easy” by at least 65% of participants. Among all participants, 57 (86.4%) were “confident”/“very confident” of glycopyrrolate administration. On a Likert scale of 1 (“I don’t like it”) to 7 (“I like it a lot”), mean scores were at least 5.9 for portability, ease of cleaning, size, weight, short administration time, and relative silence of the device. Over 80% of participants said they “probably”/"definitely" would continue to use eFlow. CONCLUSION: Based on this real-world study, the majority of patients were highly satisfied with, and confident in, using eFlow.
format Online
Article
Text
id pubmed-7369372
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-73693722020-08-05 Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow(®) CS Stephenson, Judith J Dembek, Carole Caldwell-Tarr, Amanda Conto, Rebecca M Paullin, Mark Kerwin, Edward M Int J Chron Obstruct Pulmon Dis Original Research PURPOSE: To assess clinical characteristics and device satisfaction of patients with chronic obstructive pulmonary disease (COPD) treated with glycopyrrolate/eFlow(®) Closed System (CS) nebulizer (further referred to as eFlow) under real-world conditions. PARTICIPANTS AND METHODS: Patients with COPD currently using eFlow were identified by the study sponsor. Consenting patients who met study inclusion criteria completed a cross-sectional survey that included a device satisfaction questionnaire. Means, medians, and standard deviations were calculated. RESULTS: Sixty-six patients met inclusion criteria and completed the survey. Participants’ mean ± standard deviation age was 64.9 ± 11.9 years and the majority were white (86.4%) and female (59.1%). Almost two-thirds were former smokers. Thirty-nine (59.1%) reported their COPD to be severe/very severe and 38 (57.6%) reported a COPD exacerbation resulting in a hospitalization, ER visit, or medication modification over the past 12 months. Among 55 participants who had previously used another type of nebulizer, 44 (80%) were overall “much more”/“somewhat more” satisfied with the eFlow compared with their previous nebulizer(s). Regardless of prior nebulizer use, 60 (90.9%) participants were “satisfied”/“very satisfied” overall with the eFlow. Assembly and disassembly, operation, and cleaning were perceived as being “easy”/“very easy” by at least 65% of participants. Among all participants, 57 (86.4%) were “confident”/“very confident” of glycopyrrolate administration. On a Likert scale of 1 (“I don’t like it”) to 7 (“I like it a lot”), mean scores were at least 5.9 for portability, ease of cleaning, size, weight, short administration time, and relative silence of the device. Over 80% of participants said they “probably”/"definitely" would continue to use eFlow. CONCLUSION: Based on this real-world study, the majority of patients were highly satisfied with, and confident in, using eFlow. Dove 2020-07-14 /pmc/articles/PMC7369372/ /pubmed/32764916 http://dx.doi.org/10.2147/COPD.S248760 Text en © 2020 Stephenson et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Stephenson, Judith J
Dembek, Carole
Caldwell-Tarr, Amanda
Conto, Rebecca M
Paullin, Mark
Kerwin, Edward M
Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow(®) CS
title Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow(®) CS
title_full Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow(®) CS
title_fullStr Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow(®) CS
title_full_unstemmed Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow(®) CS
title_short Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow(®) CS
title_sort observational real-world study to assess clinical characteristics and device satisfaction in patients with copd treated with glycopyrrolate/eflow(®) cs
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369372/
https://www.ncbi.nlm.nih.gov/pubmed/32764916
http://dx.doi.org/10.2147/COPD.S248760
work_keys_str_mv AT stephensonjudithj observationalrealworldstudytoassessclinicalcharacteristicsanddevicesatisfactioninpatientswithcopdtreatedwithglycopyrrolateeflowcs
AT dembekcarole observationalrealworldstudytoassessclinicalcharacteristicsanddevicesatisfactioninpatientswithcopdtreatedwithglycopyrrolateeflowcs
AT caldwelltarramanda observationalrealworldstudytoassessclinicalcharacteristicsanddevicesatisfactioninpatientswithcopdtreatedwithglycopyrrolateeflowcs
AT contorebeccam observationalrealworldstudytoassessclinicalcharacteristicsanddevicesatisfactioninpatientswithcopdtreatedwithglycopyrrolateeflowcs
AT paullinmark observationalrealworldstudytoassessclinicalcharacteristicsanddevicesatisfactioninpatientswithcopdtreatedwithglycopyrrolateeflowcs
AT kerwinedwardm observationalrealworldstudytoassessclinicalcharacteristicsanddevicesatisfactioninpatientswithcopdtreatedwithglycopyrrolateeflowcs